$ISR Headlines Wednesday's biggest gaining and

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$ISR Headlines

Wednesday's biggest gaining and declining stocks 3:44 p.m. Aug. 19, 2009 - MarketWatch

IsoRay up premarket on brain cancer results 9:24 a.m. Dec. 1, 2014 - Seeking Alpha
Accuray CyberKnife M6 System Now Available in Manhattan - Analyst Blog 6:05 p.m. Nov. 19, 2014 - Zacks.com
10-Q: ISORAY, INC. 4:06 p.m. Nov. 14, 2014 - Edgar Online - (EDG = 10Q, 10K)
IsoRay jumps on report of single surgery 11:54 a.m. Oct. 7, 2014 - Seeking Alpha
Why IsoRay (ISR) Stock Is Surging Today 10:02 a.m. Oct. 7, 2014 - TheStreet.com
Ad Comm smacks down Sonacare's HIFU device for prostate cancer 12:53 p.m. Oct. 3, 2014 - Seeking Alpha
10-K: ISORAY, INC. 3:44 p.m. Sept. 29, 2014 - Edgar Online - (EDG = 10Q, 10K)
Top Swing Trade Ideas for Thursday, Aug. 21: Alcoa, Sodastream, More 9:45 a.m. Aug. 21, 2014 - TheStreet.com
Why IsoRay (ISR) Stock Is Spiking Today 10:41 a.m. July 14, 2014 - TheStreet.com
First Cesium-131 seed implanted 8:02 a.m. July 14, 2014 - Seeking Alpha
Why IsoRay (ISR) Stock Is Surging Today 9:38 a.m. June 24, 2014 - TheStreet.com
First patient treated with Cesitrex 8:24 a.m. June 24, 2014 - Seeking Alpha
More on IsoRay fiscal Q3 results 9:16 a.m. May 16, 2014 - Seeking Alpha
10-Q: ISORAY, INC. 4:18 p.m. May 15, 2014 - Edgar Online - (EDG = 10Q, 10K)
Why IsoRay (ISR) Stock Is Surging Today 10:10 a.m. May 12, 2014 - TheStreet.com
IsoRay's Liquid Cesium-131 receives final OK for use in brain cancer 9:02 a.m. May 12, 2014 - Seeking Alpha
IsoRay (ISR) Is Today's Dead Cat Bounce Stock 8:46 a.m. May 12, 2014 - TheStreet.com
Perilous Reversal Watch: IsoRay (ISR) 8:49 a.m. May 8, 2014 - TheStreet.com
Irrational exuberance is alive and well with IsoRay 9:33 a.m. April 30, 2014 - Seeking Alpha
Why IsoRay (ISR) Stock Is Surging Today 9:30 a.m. April 30, 2014 - TheStreet.com


UPMC Study Reports IsoRay's Cesium-131 Prostate Treatment Provides Strong Cancer Control With Lower Side Effects, Providing Men Improved Quality of Life 8:16 a.m. Jan. 20, 2015 - Marketwired
IsoRay's Cesium-131 Therapy Takes Center Stage at Russia's Neftyanik Hospital a Center of Excellence Providing Cutting Edge Cancer Treatments 8:15 a.m. Jan. 13, 2015 - Marketwired
IsoRay Ranked 5th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed on the NYSE Group 8:15 a.m. Jan. 12, 2015 - Marketwired
IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer 8:03 a.m. Dec. 8, 2014 - Marketwired
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma 8:50 a.m. Dec. 4, 2014 - PR Newswire - PRF
IsoRay's Cesium-131 Therapy Stops Brain Cancers from Recurring in Treated Locations Where Previous Conventional Treatments Failed 8:20 a.m. Dec. 1, 2014 - ACCESSWIRE
IsoRays Cesium-131 Therapy Stops Brain Cancers from Recurring in Treated Locations Where Previous Conventional Treatments Failed 8:01 a.m. Dec. 1, 2014 - eTeligis
IsoRay, Inc. Reports First Quarter Results 8:01 a.m. Nov. 17, 2014 - eTeligis
IsoRay Celebrates 10 Year Success Story With the First Prostate Patient Treated With Cesium-131 7:31 a.m. Oct. 29, 2014 - ACCESSWIRE
IsoRay Celebrates 10 Year Success Story With the First Prostate Patient Treated With Cesium-131 7:17 a.m. Oct. 29, 2014 - eTeligis
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 8:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
Isoray Announces Early Success for Young Peruvian Girl Utilizing Cesium-131 in First Stereotactic Implant for Inoperable Brain Cancer 7:16 a.m. Oct. 7, 2014 - Marketwire
Isoray Announces Early Success for Young Peruvian Girl Utilizing Cesium-131 in First Stereotactic Implant for Inoperable Brain Cancer 7:06 a.m. Oct. 7, 2014 - eTeligis
IsoRay, Inc. Reports Fiscal Year 2014 Results 7:46 a.m. Sept. 30, 2014 - Marketwire
IsoRay's Cesium-131 Cancer Treatment Products and Methods to Be Featured in Oral Presentations by Industry Leaders During the American Society for Radiation Oncology Convention (ASTRO) 7:31 a.m. Sept. 9, 2014 - Marketwire
ISORAYS CESIUM-131 CANCER TREATMENT PRODUCTS AND METHODS TO BE FEATURED IN ORAL PRESENTATIONS BY INDUSTRY LEADERS DURING THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY CONVENTION (ASTRO) 7:17 a.m. Sept. 9, 2014 - eTeligis
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay 8:05 a.m. Sept. 3, 2014 - PR Newswire - PRF
IsoRay's Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as Published in the Journal of Neurosurgery 7:33 a.m. Aug. 5, 2014 - Marketwire
IsoRay's Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as Published in the Journal of Neurosurgery 7:16 a.m. Aug. 5, 2014 - eTeligis
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 7:40 a.m. July 31, 2014 - PR Newswire - PRF

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 93

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
Ensign Lawsuit Brews: Investor Stakes High by Dec. 7

Updated Category News Views 40

Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 136

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 192

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 121

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 74

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Chemours Faces Class Action Over Fraud Allegations

Updated Category News Views 246

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 183

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Updated Category News Views 208

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 150

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Fluor Corporation's Recent Class Action Developments

Updated Category News Views 255

Fluor Corporation: An Overview of Recent Developments Fluor Corporation is a global leader in providing engineering, procurement, and construction (EPC) services, along with project management support. The company is dedicated to delivering essential infrastructure and the latest technology solutions while enhancing its operational efficiencies. Class Period and...

Continue Reading
Securing Your Rights: A Call to Sarepta Therapeutics Investors

Updated Category News Views 150

Urgent Reminder for Sarepta Therapeutics Investors In light of recent legal developments, it's crucial for investors of Sarepta Therapeutics, Inc. to take action regarding their investments in this biopharmaceutical company. Investors who acquired securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) are being notified of upcoming legal deadlines that could impact their...

Continue Reading
GMT Pay Revolutionizes Everyday Spending with Web3 Earnings

Updated Category News Views 151

GMT Pay: A New Era in Payment Solutions Welcome to the exciting world of GMT Pay, the groundbreaking payment solution that allows users to turn their Web3 earnings into everyday purchases. This innovative platform is spearheaded by FSL, the development studio behind the renowned Web3 lifestyle app, STEPN. With GMT Pay, users can easily access their earnings from various...

Continue Reading
Trucept, Inc. Unveils 2022 Financial Results and Future Prospects

Updated Category News Views 40

Trucept, Inc. Announces Major Financial Developments Trucept Inc. DBA Afinida is excited to share its audited financial results for the year 2022. With a keen focus on delivering transparency, the company underscores its commitment to its shareholders and clients alike. CEO Norman Tipton expresses optimism about the upcoming 2023 financial report, which is expected to be...

Continue Reading
Bitcoin's Critical Support Level for Future Growth Explained

Updated Category News Views 174

Understanding Bitcoin's Correction Phase Bitcoin's (CRYPTO: BTC) ongoing correction phase has garnered much attention among traders and investors alike. Key Insights From Technical Analysis Technical analyst Kevin has pointed out that Bitcoin's correction patterns notably exhibit similarities across different market cycles. Historically, even amidst various macroeconomic...

Continue Reading